差异显示法分离赤霉素调控的水稻(Oryza sativa)cDNA(英文)

赤霉素(gibberellins)是植物生长发育过程中一类重要的调节激素。本文运用反转录和聚合酶链式反应建立了一套旨在分离差异表达cDNA的差异显示方法。以籼稻珍汕97 B为材料,将赤霉素GA_3处理后的苗期水稻与对照的cDNA片段进行比较,鉴定了15个差异cDNA,并将它们从测序胶中回收和再次扩增获得差异表达的cDNA;用其中一个差异cDNA片段DDF1为探针的Southern和northern杂交证实,DDF1所对应的基因是一个单拷贝基因,可被高浓度的GA_3诱导并获得高水平表达。     

邻苯二甲醛(OPA)法检测铝吸附疫苗中抗原含量

目的:建立快速测定铝胶吸附的疫苗中抗原含量的OPA荧光检测法。 方法:利用邻苯二甲醛(OPA)在2-巯基乙醇存在下与氨基酸的N端或L-谷氨酸侧链反应,在460nm处生成荧光衍生物的原理,建立了无需进行抗原蛋白提取的检测方法,并对该方法的特异性、线性、精密度、回收率、重复性进行考察。同时,配合钠十二烷基的硫酸盐-聚丙烯酰胺凝胶电泳法(SDS-PAGE),研究在配制过程中抗原蛋白与佐剂是否分离。结果: OPA荧光法,在抗原蛋白含量为0.02~0.16mg/ml时,线性良好,准确度达90%~115%,批内和批间相对标准偏差≤15%。电泳结果显示,CpG的加入可能会导致少量抗原蛋白从铝胶中解离。结论:该方法快速、准确、灵敏度较高,重复性好,可以应用于含铝胶疫苗制剂的实验室甚至生产质控过程。     

赤霉素破除马铃薯脱毒原原种休眠的研究(简报)

赤霉素能有效地破除马铃薯脱毒原原种的休眠。用１０ｍｇ．Ｌ＾－１赤素和５ｍｇ．Ｌ＾－１赤霉素＋１％硫脲混合液喷湿处理收获后贮存１５ｄ的原原种效果最好。用已萌芽的脱毒原帮种播种长出的幼苗生长健壮。质量浓度３０ｍｇ．Ｌ＾－１的赤霉素节同伸长,长成纤细苗。     

赤水丹霞土壤链霉菌CSDX 001来源的新苯邻二甲酰亚胺的分离及结构鉴定

利用改良的GYM培养基对从赤水丹霞山土壤样品中分离的链霉菌分离菌株Streptomyces sp.CSDX 001进行固体发酵,发酵产物利用乙酸乙酯萃取,减压浓缩、富集获得其粗提取物。利用反复硅胶柱层析对粗提物中的次级代谢产物进行分离纯化,通过质谱、核磁共振等波谱方法对分离产物进行结构鉴定。从链霉菌Streptomyces sp.CSDX 001中分离得到2个化合物,分别为苯邻二甲酰亚胺4-羟基-N,7-二甲基苯邻酰亚胺(1)和2-甲基-2,5-莰二醇(2),其中化合物1为新化合物。     

赤霉素对大岩桐花蕾离体培养直接再生花芽的影响(简报)

植物经过一定时期的营养生长(或感受外界信号)后,就能产生成花刺激物。成花刺激物被运输到茎尖,诱导发生一系列的反应。随后其分生组织在一定时期内处于一个相对稳定的状态,即成花决定态。植物成花决定态建立的过程称为成花决定。对     

外源赤霉素(GA3)对青花菜花芽分化和花球发育的影响

喷施GA3可在一定程度上促进青花菜的花芽分化进程,因而使花球的现蕾期、膨大期和采收始期相应提前,50mg·L-1GA3处理的最佳,产量和花球紧实度也增加,喷施100 mg·L-1 GA3的青花菜花球维生素C含量显著下降.     

赤霉素及竹红菌甲素荧光量子产率的常量化区域

通过对赤毒素、竹红菌甲素及苯酚量子产率的测定与比较发现,这三种荧光化合物都具有一个相对于激发波长的量子产率的稳定区域。尽管它们具有多个激发峰,但不同激发峰所激发的荧光量子产率差别较小。竹红菌甲素在室温放置一个月,690nm荧光光谱有明显的改变。以上结果提示在测定未知荧光化合物的量子产率时,被测溶液的散射较强,同时荧光物的激发与发射波长彼此相接近。量子产率较弱时,可以在最大激发峰的蓝移方向上选择激发波长来避免散射光的干扰,提高量子产率测定的准确度。竹红菌甲素在690nm的荧光肩峰,可能是分子空间结构上容易发     

邻苯二甲醛与戊二醛消毒消化内镜的比较研究

目的 对新型消毒剂邻苯二甲醛(OPA)的消化内镜消毒效果与戊二醛的进行比较研究.方法 用细菌培养的方法随机研究OPA与戊二醛消毒消化内镜的效果,并比较其临床优劣.结果 有效浓度的OPA和戊二醛在按照要求使用的情况下,所有检测的内镜细菌培养都未见细菌生长,但前者消毒所需时间更短,临床使用更安全.结论 OPA可以有效的对消化内镜进行消毒,与戊二醛相比有临床优势.     

Exendin-4类似物的克隆、表达与体内生物活性检测

为研究Exendin-4类似物的克隆,融合表达及在体内的生物活性,在pED载体融合伴侣序列中插入利于下游分离纯化的序列成为5#载体,将Exendin-4类似物基因与5#载体中的融合伴侣基因通过酸水解位点连接,转化至E.coli BL21中并诱导表达融合蛋白,酸水解将目的肽与融合伴侣分开后,经阴离子交换树脂分离得到目的肽。6周～8周正常雄性ICR小鼠皮下注射Exendin-4类似物后,口服糖耐量实验检测在不同时间段小鼠血液中葡萄糖及胰岛素含量的变化。结果表明:融合蛋白的表达量占菌体总蛋白的40%,Exendin-4类似物纯度达91.8%。Exendin-4类似物的活性与对照组相比,具有显著的降低血糖和显著促进胰岛素分泌的活性(P<0.01)。     

双链季铵盐复合邻苯二甲醛消毒液研制及比较

通过将邻苯二甲醛、双链季铵盐与相应助剂进行复配,制备一种新型的复合消毒剂,并进行灭菌消毒试验、清洗效果及稳定性试验。实验证明邻苯二甲醛复合消毒剂浓度在2000 mg/L时对白色念珠菌的杀灭效果达100%。该复合消毒剂原液经45℃恒温放置15 d,邻苯二甲醛的下降率为2.26%左右,稳定性和杀菌能力有明显提高。对油脂清洗率达98%以上,具有消毒清洗双功能。因此邻苯二甲醛复合消毒剂对消化内镜消毒灭菌效果高,耗时短,用法简便,并可降低对医务人员健康的危害性,是值得在医院临床推广使用的高效消毒剂。     

Stimulation of weed seed germination by 1–(3-chlorophthalirnido) cyclohexanecarboxamide (AC 94377)

The N-substituted phthalimide, AC 94377, promoted the germination of dry-stored seeds of 17 out of 24 weed species in Petri-dish tests maintained at 22°C. In a further test it was able to substitute for light and/or alternating temperatures in promoting the germination of some species. AC 94377 was more active than GA, in stimulating Solanum nigrum seed to germinate. When mixed with soil in the laboratory, AC 94377 again promoted germination of S. nigrum but the level and persistence of activity differed between soils. In the glasshouse, with soil containing a natural weed seed population, more seedlings emerged from treated than from untreated soil but this number represented fewer than half of the apparently viable seeds present. Field applications of AC 94377 promoted the germination of hand-sown seeds of certain weed species but did not increase the number of seedlings emerging from the natural weed seed bank.     

A Novel Phthalimide Derivative,TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma-bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the C_max was 2.1 μM at 1 h after the injection of TC11, with 1.2 h as the half-life. TC11 significantly inhibited the differentiation and function of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts in mouse osteoclast cultures using M-CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by α-tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high-risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.     

Synthesis,Structural and Antioxidant Studies of Some Novel N-Ethyl Phthalimide Esters

A series of N-ethyl phthalimide esters 4(a-n) were synthesized and characterized by spectroscopic studies. Further, the molecular structure of majority of compounds were analysed by single crystal X-ray diffraction studies. The X-ray analysis revealed the importance of substituents on the crystal stability and molecular packing. All the synthesized compounds were tested for in vitro antioxidant activity by DPPH radical scavenging, FRAP and CUPRAC methods. Few of them have shown good antioxidant activity.     

Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity

As a member of the class III histone deacetylases, Sirtuin-2 (SIRT2) is critical in cell cycle regulation which makes it a potential target for cancer therapeutics. In this study, we identified a novel SIRT2 inhibitor, AC-93253, with IC₅₀ of 6 μM in vitro. The compound is selective, inhibiting SIRT2 7.5- and 4-fold more potently than the closely related SIRT1 and SIRT3, respectively. AC-93253 significantly enhanced acetylation of tubulin, p53, and histone H4, confirming SIRT2 and SIRT1 as its cellular targets. AC-93253 as a single agent exhibited submicromolar selective cytotoxicity towards all four tumor cell lines tested with a therapeutic window up to 200-fold, comparing to any of the three normal cell types tested. Results from high content analysis suggested that AC-93253 significantly triggered apoptosis. Taken together, SIRT2 selective inhibitor AC-93253 may serve as a novel chemical scaffold for structure-activity relationship study and future lead development.     

Efficient Phthalimide Copolymer‐Based Bulk Heterojunction Solar Cells: How the Processing Additive Influences Nanoscale Morphology and Photovoltaic Properties

The power conversion efficiency of poly(N‐(2‐ethylhexyl)‐3,6‐bis(4‐dodecyloxythiophen‐2‐yl)phthalimide) (PhBTEH)/fullerene bulk heterojunction solar cells improves from 0.43 to 4.1% by using a processing additive. The underlying mechanism for the almost 10‐fold enhancement in solar cell performance is found to be inhibition of fullerene intercalation into the polymer side chains and regulation of the relative crystallization/aggregation rates of the polymer and fullerene. An optimal interconnected two‐phase morphology with 15–20 nm domains is obtained when a processing additive is used compared with 100–300 nm domains without the additive. The results demonstrate that a processing additive provides an effective means of controlling both the fullerene intercalation in polymer/fullerene blends and the domain sizes of their phase‐separated nanoscale morphology.     

Phthalimide Polymer Donor Guests Enable over 17% Efficient Organic Solar Cells via Parallel‐Like Ternary and Quaternary Strategies

Ternary strategies show over 16% efficiencies with increased current/voltage owing to complementary absorption/aligned energy level contributions. However, poor understanding of how the guest components tune the active layer structures still makes rational selection of material systems challenging. In this study, two phthalimide based ultrawide bandgap polymer donor guests are synthesized. Parallel energies between the highest occupied molecular orbitals of host and guest polymers are achieved via incorporating selnophene on the guest polymer. Solid‐state ¹⁹F magic angle spinning nuclear magnetic spectroscopy, graze‐incidence wide‐angle X‐ray diffraction, elemental transmission electron microscopy mapping, and transient absorption spectroscopy are combined to characterize the active layer structures. Formation of the individual guest phases selectively improves the structural order of donor and acceptor phase. The increased electron mobility in combination with the presence of the additional paths made by the guest not only minimizes the influence on charge generation and transport of the host system but also contributes to increasing the overall current generation. Therefore, phthalimide based polymers can be potential candidates that enable the simultaneous increase of open‐circuit voltage and short‐circuit current‐density via fine‐tuning energy levels and the formation of additional paths for enhancing current generation in parallel‐like multicomponent organic solar cells.     

Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review

Retinoic acid receptors (RARs) α, β, and γ are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids which regulate a wide variety of biological processes such as vertebrate embryonic morphogenesis and organogenesis, cell growth arrest, differentiation, and apoptosis, as well as their disorders. Although many synthetic selective RARα, RARβ, and RARγ agonists have been designed and prepared, these have generally been lipophilic acids without good drug-like properties and with low oral bioavailability. Recently this has been changing and drug design approaches to highly potent and selective RARα and RARβ agonists with low lipophilicity that are orally bioavailable and less toxic have been developed, that have a range of potential therapeutic uses. This review covers these new advances.